| 
																	
																	
																		 Connection
 
																		  Viralkumar  Shah  to  Treatment Outcome 
																		
																	 
																		 This is a "connection" page, showing publications  Viralkumar  Shah  has written about  Treatment Outcome.  
																		
																	 
																			
																					
	
						
				
		
			
			
			|  | 
				
					|  | Connection Strength |  |  
					|  |   |  |  
					|  | 0.867 |  |  |  |  
		
		
			
				Shah VN, Akturk HK, Kruger D, Ahmann A, Bhargava A, Bakoyannis G, Pyle L, Snell-Bergeon JK. Semaglutide in Adults with Type 1 Diabetes and Obesity. NEJM Evid. 2025 Aug; 4(8):EVIDoa2500173.	
				
				
					Score: 0.085
				
				Shah VN, Dex T, Meneghini L, Rodrigues A, Polonsky WH. Treatment satisfaction and time in range after 16?weeks of treatment with iGlarLixi in insulin-naive adults with suboptimally controlled type 2 diabetes. Diabetes Obes Metab. 2025 May; 27(5):2523-2530.	
				
				
					Score: 0.083
				
				Fr?as JP, Ratzki-Leewing A, Dex T, Meneghini L, Rodrigues A, Shah VN. Effect of iGlarLixi on continuous glucose monitoring-measured time in range in insulin-naive adults with suboptimally controlled type 2 diabetes. Diabetes Obes Metab. 2025 Apr; 27(4):2173-2182.	
				
				
					Score: 0.083
				
				Shah VN, Agesen RM, Bardtrum L, Christiansen E, Snaith J, Greenfield JR. Determinants of Liraglutide Treatment Discontinuation in Type 1 Diabetes: A Post Hoc Analysis of ADJUNCT ONE and ADJUNCT TWO Randomized Placebo-Controlled Clinical Studies. J Diabetes Sci Technol. 2025 Mar; 19(2):321-331.	
				
				
					Score: 0.082
				
				Klein MP, Akturk HK, Snell-Bergeon JK, Shah VN. Reduced Efficacy of Glucagon-Like Peptide-1 Receptor Agonists Therapy in People With Type 1 Diabetes and Genetic Forms of Obesity. J Diabetes Sci Technol. 2025 Mar; 19(2):297-303.	
				
				
					Score: 0.078
				
				Shah VN, Al-Karadsheh A, Barnes C, Mandry J, Nakhle S, Wernicke-Panten K, Kramer D, Schmider W, Pierre S, Teichert L, Rotthaeuser B, Mukherjee B, Bailey TS. Safety and Efficacy of Switching SAR341402 Insulin Aspart and Originator Insulin Aspart vs Continuous Use of Originator Insulin Aspart in Adults With Type 1 Diabetes: The GEMELLI X Trial. J Diabetes Sci Technol. 2025 Jul; 19(4):1051-1059.	
				
				
					Score: 0.078
				
				Akturk HK, Dong F, Snell-Bergeon JK, Karakus KE, Shah VN. Efficacy and Safety of Tirzepatide in Adults With Type 1 Diabetes: A Proof of Concept Observational Study. J Diabetes Sci Technol. 2025 Mar; 19(2):292-296.	
				
				
					Score: 0.077
				
				Garg SK, Wernicke-Panten K, Wardecki M, Kramer D, Delalande F, Franek E, Sadeharju K, Monchamp T, Mukherjee B, Shah VN. Efficacy and Safety of Insulin Aspart Biosimilar SAR341402 Versus Originator Insulin Aspart in People with Diabetes Treated for 26 Weeks with Multiple Daily Injections in Combination with Insulin Glargine: A Randomized Open-Label Trial (GEMELLI 1). Diabetes Technol Ther. 2020 02; 22(2):85-95.	
				
				
					Score: 0.058
				
				Kaur H, Schneider N, Pyle L, Campbell K, Akturk HK, Shah VN. Efficacy of Hybrid Closed-Loop System in Adults with Type 1 Diabetes and Gastroparesis. Diabetes Technol Ther. 2019 12; 21(12):736-739.	
				
				
					Score: 0.057
				
				Mulinacci G, Alonso GT, Snell-Bergeon JK, Shah VN. Glycemic Outcomes with Early Initiation of Continuous Glucose Monitoring System in Recently Diagnosed Patients with Type 1 Diabetes. Diabetes Technol Ther. 2019 01; 21(1):6-10.	
				
				
					Score: 0.054
				
				Shah VN, Bhadada S, Bhansali A, Behera A, Mittal BR. Changes in clinical & biochemical presentations of primary hyperparathyroidism in India over a period of 20 years. Indian J Med Res. 2014 May; 139(5):694-9.	
				
				
					Score: 0.039
				
				Shah VN, Shah CS, Bhadada SK, Rao DS. Effect of 25 (OH) D replacements in patients with primary hyperparathyroidism (PHPT) and coexistent vitamin D deficiency on serum 25(OH) D, calcium and PTH levels: a meta-analysis and review of literature. Clin Endocrinol (Oxf). 2014 Jun; 80(6):797-803.	
				
				
					Score: 0.039
				
				Levy CJ, Bailey R, Laffel LM, Forlenza G, DiMeglio LA, Hughes MS, Brown SA, Aleppo G, Bhargava A, Shah VN, Clements MA, Kipnes M, Bruggeman B, Daniels M, Rodriguez H, Calhoun P, Lum JW, Sasson-Katchalski R, Pinsker JE, Pollom R, Beck RW. Multicenter Evaluation of Ultra-Rapid Lispro Insulin with Control-IQ Technology in Adults, Adolescents, and Children with Type 1 Diabetes. Diabetes Technol Ther. 2024 Sep; 26(9):652-660.	
				
				
					Score: 0.020
				
				Polsky S, Wu M, Bode BW, DuBose SN, Goland RS, Maahs DM, Foster NC, Peters AL, Levy CJ, Shah VN, Beck RW. Diabetes Technology Use Among Pregnant and Nonpregnant Women with T1D in the T1D Exchange. Diabetes Technol Ther. 2018 08; 20(8):517-523.	
				
				
					Score: 0.013
				
				Bally L, Thabit H, Tauschmann M, Allen JM, Hartnell S, Wilinska ME, Exall J, Huegel V, Sibayan J, Borgman S, Cheng P, Blackburn M, Lawton J, Elleri D, Leelarathna L, Acerini CL, Campbell F, Shah VN, Criego A, Evans ML, Dunger DB, Kollman C, Bergenstal RM, Hovorka R. Assessing the effectiveness of a 3-month day-and-night home closed-loop control combined with pump suspend feature compared with sensor-augmented pump therapy in youths and adults with suboptimally controlled type 1 diabetes: a randomised parallel study protocol. BMJ Open. 2017 Jul 13; 7(7):e016738.	
				
				
					Score: 0.012
				
				Sooragonda B, Bhadada SK, Shah VN, Malhotra P, Ahluwalia J, Sachdeva N. Effect of vitamin D replacement on hemoglobin concentration in subjects with concurrent iron-deficiency anemia and vitamin D deficiency: a randomized, single-blinded, placebo-controlled trial. Acta Haematol. 2015; 133(1):31-5.	
				
				
					Score: 0.010
				 | 
																	
																		
																			
																					    Connection Strength   
  The connection strength for concepts is the sum of the scores for each matching publication.  
 Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
 |